Vanda Pharmaceuticals Return on Equity:
-130.8% for Dec. 31, 2012Vanda Pharmaceuticals Historical Return on Equity Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| Dec. 31, 2012 | -130.8% |
| Sept. 30, 2012 | -100.4% |
| June 30, 2012 | -77.89% |
| March 31, 2012 | -50.51% |
| Dec. 31, 2011 | -26.07% |
| Sept. 30, 2011 | -5.51% |
| June 30, 2011 | 11.54% |
| March 31, 2011 | 20.22% |
| Dec. 31, 2010 | 23.72% |
| Sept. 30, 2010 | -14.81% |
| June 30, 2010 | -53.20% |
| March 31, 2010 | -93.45% |
| Dec. 31, 2009 | -103.3% |
About Return on Equity (ROE)
Return on equity (ROE) measures the rate of return on the money invested by common stock owners and retained by the company thanks to previous profitable years. It demonstrates a company's ability to generate profits from shareholders' equity (also known as net assets or assets minus liabilities).
ROE shows how well a company uses investment funds to generate growth. Return on equity is useful for comparing the profitability of companies within a sector or industry.
Investors generally are interested in company's that have high, increasing returns on equity.
Learn More
VNDA Return on Equity Benchmarks
| Companies | |
|---|---|
| Oramed Pharmaceuticals | -103.5% |
| Stemline Therapeutics | -2100% |
| Tesaro | -65.38% |
VNDA Return on Equity Rankings
| Overall |
43rd percentile 4501 of 8005 |
| Sector |
33rd percentile 458 of 686 in Healthcare |
| Industry |
45th percentile 136 of 248 in Biotechnology |
VNDA Return on Equity Range, Past 5 Years
| Minimum | -130.8% | Dec 2012 |
| Maximum | 23.72% | Dec 2010 |
| Average | -57.52% |
VNDA News
Unusual 11 Mid-Day Movers 05/17: (RSOL) (SCTY) (VNDA) Higher; (ARUN) (UNXL) (COSI) Lower
Street Insider May 17
Street Insider May 17
